|
|
|
|
|
Rheoscience and Dr. Reddy’s commence the first Phase III
trial of Balaglitazone (DRF 2593)
August 01, 2007 |
|
Dr. Reddy’s Q1 FY08 revenue at Rs 12,018 million;
Net income at Rs 1,825 million;
July 23, 2007 |
|
Dr. Reddy's to release Q1 FY08 results on July 23, 2007;
Earnings call slated for July 23, 6.30 PM IST/9.00 AM EST
July 18, 2007 |
|
Dr. Reddy's launches Glimy MP 1 and Glimy MP2. Triple drug combination ideal to address the triple defects in diabetes
July 10, 2007 |
|
Dr. Reddy's commences operations in Nigeria.
June 15, 2007 |
|
Dr. Reddy's enters the Dermatology topical steroid market with the launch of ‘UltravexTM’ - (Halobetasol)
June 08, 2007 |
|
Dr. Reddy’s FY07 revenue at Rs. 65,095 million (US$ 1.5 billion); Net income at Rs. 9,327 million (US$ 216 million);
May 18, 2007 |
|
Dr. Reddy’s announces new R&D Chief
April 30, 2007 |
|
Dr. Reddy’s launches Reditux™ – Monoclonal Antibody Treatment for Non-Hodgkin’s Lymphoma
April 30, 2007 |
|
Dr. Reddy’s Q3 FY07 revenue at Rs 15,434 million; Net income at Rs 1,879 million; Nine Months Revenues cross USD 1 billion
January 22, 2007 |
